Cristian BELLODI, PhD

Assistant Professor, Lund University

Expertise: RNA & Cancer Biology

​

"I devoted my scientific career to uncovering new regulatory facets governed by ribonucleic acid (RNA), one of life’s indispensable molecules, during the earliest and critical steps of development and tumorigenesis. My research investigates how ancient chemical modifications impact RNA function and “reprogram” cell fate at a molecular, cellular, and organismal level. I co-founded SACRA to innovate our discoveries into RNA-based therapeutic strategies for treating life-threatening hematological and solid cancers, often characterized by defects in RNA metabolism"

​

Ana BOSCH CAMPOS, MD, PhD

Medical Oncologist

Expertise: Breast Cancer & Clinical Trial Development

​

"I have worked as a medical oncologist for 20 years and witnessed that the exponential knowledge in the genomic field has not necessarily translated into the expected exponential improvement in cancer outcome and survival. Targeting the epitranscriptome is the new frontier in cancer therapeutics that will bridge the gap between science and patient care, and working in SACRA Therapeutics allows me to be part of the solution"

Sowndarya MUTHUKUMAR, PhD

Postdoctoral Fellow

Expertise: RNA & Protein Structural Biology

 

"As an early career researcher, it is a great experience to be able to witness first-hand the transition of basic research from bench to bedside. RNA epitranscriptomics is revolutionising the landscape of cancer biology and we at SACRA Therapeutics explore this unconventional therapeutic platform.  As founding CEO, I have been part of rapidly progressing, innovative science advancing our knowledge of the molecular events underlying incurable forms of cancer. This will pave the way for future therapeutic avenues aimed at developing more precise treatment for patients"

Martina KVIST REIMER, PhD

Executive Vice President Red Glead Discovery

Expertise: Drug Discovery & Clinical Development

​

"There is incredible potential in SACRA Therapeutics for breakthrough innovation by utilizing novel molecular pathways in epitranscriptomics. The Team is pushing the knowledge frontier in this exciting field, which holds great promise for the discovery and development of novel and transformative therapies for patients in need. We share the vision of delivering life-changing medicines, creating value for patients and society. The entrepreneurial spirit and the excellent science created at SACRA is providing an extremely stimulating environment, making me proud to be part of this endeavor"